Bhavna PTE Limited Pharmaceutical Import Profile — Singapore (DGFT 2022–2026)

Name: Bhavna PTE Limited Pharmaceutical Import Records from India — 2 Products, $494.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bhavna PTE Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $494.7K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Bhavna PTE Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Accra Pac (india) Private Limited	$110.7K	6	57.2%
Accra Pac India Private Limited	$46.3K	2	23.9%
Crystal Overseas	$28.1K	2	14.5%
Monarch International	$8.5K	5	4.4%

Bhavna PTE Limited sources from 4 verified Indian suppliers across 14 distinct formulations. The supply base is diversified across 4 suppliers, reducing single-source dependency risk.

What Formulations Does Bhavna PTE Limited Import?

Formulation	Value	Ships
Moov rapid relief spray 150ML (batch	$50.0K	1
Moov rapid relief spray 150ML batch number - b3131e5e / b3132e5e / b3133e5e (1500 cases )	$47.3K	1
Moov rapid relief spray 150ML batch number-b3097e5e qty 1500 cases Pack size 1500 x 48 =	$46.3K	1
Dettol liquid 550ML	$28.1K	2
Moov rapid relief spray 80g batch number - b3136d5e ( 200 cases )	$6.3K	1
Moov pain relief specialist spray 80g	$3.9K	1
Navratna oil (1pcs=270ML) [of	$3.3K

What Products Does Bhavna PTE Limited Import?

Top Products by Import Value

1Moov$400.7K 2Dettol$94.0K

Bhavna PTE Limited Therapeutic Categories — 1 Specializations

Bhavna PTE Limited imports across 1 therapeutic categories, with Brand Names & OTC Products (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Brand Names & OTC Products

2 products · 100.0% · $494.7K

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Moov	Brand Names & OTC Products	$400.7K	18	1.5%	9
2	Dettol	Brand Names & OTC Products	$94.0K	6	1.1%	13

Key Metrics

Total Import Value$494.7K

Products2

Shipments24

Categories1

CountrySingapore

#1 Rankings0

Indian Suppliers4

Formulations14

Top Categories

Brand Names & OTC Products100.0%

Indian Suppliers

Last updated: March 28, 2026

Bhavna PTE Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Bhavna PTE Limited, established in 1985, is a privately held company headquartered in Singapore. Over the years, it has evolved into a prominent player in the Fast-Moving Consumer Goods (FMCG) sector, specializing in the wholesale import and export of a diverse range of products. The company offers services such as regulatory compliance, brand management, procurement, sales and distribution, as well as logistics and warehousing. (bhavna.com.sg)

While Bhavna PTE Limited's primary focus is on FMCG, it also engages in the importation of pharmaceutical products. This strategic diversification allows the company to leverage its extensive distribution network and market expertise to cater to the pharmaceutical sector's demands. The company's global presence is underscored by its operations in over 75 countries, facilitated through partner offices in regions including Southeast Asia, South Asia, North Asia, the Middle East, and North America. (bhavna.com.sg)

2Distribution Network

Bhavna PTE Limited's distribution network is strategically designed to ensure efficient market penetration and product availability. In Singapore, the company operates from its headquarters at 5 Pereira Road #04-03, Asia Wide Industrial Building, Singapore 368025. (bhavna.com.sg) Additionally, Bhavna maintains a warehouse at 3 Upper Aljunied Link #02-06, Joo Seng Warehouse, Singapore 367902, enhancing its logistical capabilities within the region.

Supplier Relationship Intelligence — Bhavna PTE Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Bhavna PTE Limited's sourcing strategy exhibits a notable concentration, with a significant portion of its pharmaceutical imports originating from a select group of suppliers. The company's total import value from India stands at $495,000 USD, distributed across 24 shipments. The top five products imported include Moov ($401,000 USD, Rank #9, 1.5% share) and Dettol ($94,000 USD, Rank #13, 1.1% share). The top five products collectively account for 100% of the company's pharmaceutical imports, indicating a high level of portfolio concentration.

This sourcing pattern suggests a strategic focus on specific high-demand products, potentially leveraging established relationships with key suppliers. However, the lack of diversification in the supplier base may pose risks related to supply chain disruptions or changes in supplier dynamics. The stability of these relationships is crucial for maintaining a consistent supply of the imported pharmaceutical products.

2Supply Chain Resilience

The resilience of Bhavna PTE Limited's supply chain is closely tied to its reliance on a limited number of suppliers for its pharmaceutical imports. The company's import data reveals that four unique Indian suppliers account for the entirety of its pharmaceutical imports. This concentrated supplier base may expose Bhavna to potential risks, such as supply chain disruptions, price fluctuations, or changes in supplier policies.

To enhance supply chain resilience, Bhavna could consider diversifying its supplier network and establishing relationships with additional manufacturers. This approach would mitigate risks associated with over-reliance on a few suppliers and ensure a more robust and flexible supply chain capable of adapting to market changes and demands.

3Strategic Implications

Bhavna PTE Limited's concentrated sourcing strategy positions the company to negotiate favorable terms with its key suppliers, potentially securing competitive pricing and priority access to high-demand products. This focus allows Bhavna to streamline its operations and maintain a consistent product offering in the Singaporean market.

For Indian pharmaceutical exporters, the concentration of Bhavna's imports presents an opportunity to strengthen existing partnerships and explore avenues for expanding product offerings within Bhavna's portfolio. By aligning with Bhavna's strategic focus, Indian exporters can enhance their market presence in Singapore and benefit from Bhavna's established distribution network.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Singapore — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Singapore

1Regulatory Authority & Framework

In Singapore, the Health Sciences Authority (HSA) serves as the primary regulatory body overseeing the importation, supply, and manufacture of health products, including pharmaceuticals. The HSA operates under the Health Products Act and the Medicines Act, ensuring that all health products meet stringent standards of safety, quality, and efficacy. (moh.gov.sg)

The regulatory framework mandates that all medicinal products, including generics, undergo evaluation and approval by the HSA before they can be supplied in Singapore. This process involves assessing the products for compliance with Good Manufacturing Practice (GMP) standards and other regulatory requirements. (moh.gov.sg)

2Import Licensing & GMP

Importers of medicinal products into Singapore must obtain the necessary licenses and approvals from the HSA. For instance, an 'Import License on Consignment Basis' is required for importers who are neither the registrants nor authorized by the registrant of the therapeutic product. This license permits the importation of registered therapeutic products on a per consignment basis. (hsa.gov.sg)

Additionally, the HSA requires evidence of GMP compliance from drug substance manufacturers. Effective October 1, 2024, all new or generic drug applications must be supported by GMP compliance evidence for drug substance manufacturers. This requirement aims to ensure that imported pharmaceutical products adhere to high manufacturing standards.

3Quality & Labeling

Imported pharmaceutical products must comply with HSA's quality standards, which include batch testing and stability requirements to ensure product safety and efficacy. Labeling must meet specific criteria, including accurate product information and compliance with HSA's guidelines. While the HSA does not mandate labeling in a specific language, it is common practice to provide labeling in English to ensure clarity and understanding among consumers and healthcare professionals.

4Recent Regulatory Changes

In July 2023, the HSA invited public feedback on the proposed Health Products (Active Ingredients) Regulations 2023. This initiative aims to streamline and risk-based regulatory controls for active ingredients used in health products, ensuring consistent quality standards. The proposed regulations are expected to impact companies involved in the importation and distribution of pharmaceutical products, including Bhavna PTE Limited. (hsa.gov.sg)

TransData Nexus Research · Singapore regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Bhavna PTE Limited identified across shipments using consignee name normalization, aggregating 3 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Bhavna PTE Limited's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 24 individual customs records matching Bhavna PTE Limited.
5.Supplier Verification: Bhavna PTE Limited sources from 4 verified Indian suppliers across 14 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Bhavna PTE Limited

Bhavna PTE Limited — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Bhavna PTE Limited?

What Formulations Does Bhavna PTE Limited Import?

What Products Does Bhavna PTE Limited Import?

Top Products by Import Value

Bhavna PTE Limited Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Indian Suppliers

Bhavna PTE Limited — Corporate Profile & Information

1Company Overview

2Distribution Network

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Bhavna PTE Limited

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Singapore — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Bhavna PTE Limited — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Bhavna PTE Limited

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Bhavna PTE Limited

What products does Bhavna PTE Limited import from India?

Who supplies pharmaceuticals to Bhavna PTE Limited from India?

What is Bhavna PTE Limited's total pharmaceutical import value?

What therapeutic categories does Bhavna PTE Limited focus on?

Get Full Bhavna PTE Limited Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology